SS
EVLO

Steve Schonfeld’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Steve Schonfeld’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-955
Closed -$40K – 3205
2022
Q3 		$40K Sell
955
-10
-1% -$457 ﹤0.01% 2664
2022
Q2 		$40K Sell
965
-25
-3% -$1.16K ﹤0.01% 2253
2022
Q1 		$67K Buy
+990
New +$82.4K ﹤0.01% 2298

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's EVLO Position: Q4 2022 in Review

Steve Schonfeld sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2022, closing a stake of 955 shares — an estimated $40K sold.

Steve Schonfeld first reported a position in EVLO in Q1 2022 and held it in 3 quarters. The position peaked at $67K in Q1 2022. 44 funds tracked by Wall St. Rank hold EVLO as of Q4 2022.

  • Steve Schonfeld reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Steve Schonfeld sold 955 Evelo Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $40K.
  • Steve Schonfeld first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Steve Schonfeld's Evelo Biosciences, Inc. Common Stock position peaked at $67K in Q1 2022.
  • 44 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.